Cochrane · systematic review · CD013206
Systemic treatments for eczema: a network meta‐analysis
Sawangjit, R, Dilokthornsakul, P, Lloyd-Lavery, A, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
35
current version
GRADE rated
25
No studies
6
Included studies
NR
No studies 6 · 17.1%Ungraded 4 · 11.4%Very low 14 · 40%Low 9 · 25.7%Moderate 1 · 2.9%High 1 · 2.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings for EASI75 during short‐term follow‐up
Population: patients with moderate to severe eczema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Placebo | no estimate extracted | NR | No studies |
Summary of findings for EASI75 during long‐term follow‐up
Population: patients with moderate to severe eczema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Placebo | no estimate extracted | NR | No studies |
Summary of findings for POEM scores during short‐term follow‐up
Population: patients with moderate to severe eczema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total studies: 6 RCTsTotal participants: 2680 | no estimate extracted | 6 studies · 2680 participants | Ungraded |
Dupilumab (5 RCTs; 1997 participants) | no estimate extracted | 5 studies · 1997 participants | High |
Placebo | no estimate extracted | NR | No studies |
Summary of findings for patients with SAEs during short‐term follow‐up
Population: patients with moderate to severe eczema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total studies: 17 RCTsTotal participants: 3972 | no estimate extracted | 17 studies · 3972 participants | Ungraded |
QAW039 (1 RCT; 76 participants) | RR 0.09 [0.01, 0.76] | 1 study · 39 participants | Moderate |
Dupilumab (9 RCTs; 1663 participants) | RR 0.37 [0.23, 0.59] | 9 studies · 1663 participants | Low |
Timapiprant (1 RCT; 70 participants) | RR 0.34 [0.07, 1.62] | 1 study · 70 participants | Low |
Tezepelumab (1 RCT; 56 participants) | RR 0.65 [0.11, 3.77] | 1 study · 56 participants | Low |
Lebrikizumab (1 RCT; 156 participants) | RR 0.85 [0.17, 4.25] | 1 study · 156 participants | Very low |
PF‐04965842 (1 RCT; 211 participants) | RR 0.93 [0.2, 4.35] | 1 study · 4965842 participants | Very low |
Tralokinumab (1 RCT; 153 participants) | RR 1.67 [0.2, 13.93] | 1 study · 153 participants | Very low |
Apremilast (1 RCT; 121 participants) | RR 3.73 [0.2, 71.1] | 1 study · 121 participants | Low |
Baricitinib (1 RCT; 75 participants) | RR 4.61 [0.24, 87.25] | 1 study · 75 participants | Very low |
Placebo | no estimate extracted | NR | No studies |
Summary of findings for patients with SAEs during long‐term follow‐up
Population: patients with moderate to severe eczema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total studies: 6 RCTsTotal participants: 1720 | no estimate extracted | 6 studies · 1720 participants | Ungraded |
Dupilumab (3 RCTs; 1082 participants) | RR 0.68 [0.38, 1.21] | 3 studies · 1082 participants | Low |
Methotrexate (1 RCT; 50 participants) | RR 1.15 [0.01, 151.54] | 1 study · 50 participants | Very low |
Fezakinumab (1 RCT; 40 participants) | RR 2.56 [0.13, 50.95] | 1 study · 40 participants | Very low |
QGE031 (1 RCT; 10 participants) | RR 3 [0.14, 65.9] | 1 study · 31 participants | Very low |
Cyclosporin A (2 RCTs; 49 participants) | RR 3.67 [0.09, 149.2] | 2 studies · 49 participants | Very low |
Placebo | no estimate extracted | NR | No studies |
Summary of findings for patients with infections during short‐term follow‐up
Population: patients with moderate to severe eczema
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total studies: 13 RCTsTotal participants: 1658 | no estimate extracted | 13 studies · 1658 participants | Ungraded |
Corticosteroid (1 RCT; 21 participants) | RR 0.15 [0.01, 4.1] | 1 study · 21 participants | Very low |
Dupilumab (4 RCTs; 990 participants) | RR 0.43 [0.18, 1.06] | 4 studies · 990 participants | Very low |
Cyclosporin A (3 RCTs; 74 participants) | RR 0.75 [0.1, 5.75] | 3 studies · 74 participants | Very low |
Lebrikizumab (1 RCT; 156 participants) | RR 0.79 [0.17, 3.79] | 1 study · 156 participants | Very low |
Timapiprant (1 RCT; 70 participants) | RR 0.82 [0.16, 4.14] | 1 study · 70 participants | Low |
CIM331 (1 RCT; 27 participants) | RR 0.87 [0.16, 4.63] | 1 study · 331 participants | Low |
GBR830 (1 RCT; 46 participants) | RR 1.04 [0.12, 8.81] | 1 study · 830 participants | Low |
Azathiopine (AZA) (1 RCT; 41 participants) | RR 1.14 [0.16, 8.11] | 1 study · 41 participants | Low |
QAW039 (1 RCT; 76 participants) | RR 2.66 [0.34, 21.18] | 1 study · 39 participants | Very low |
CsAI (1 RCT; 40 participants) | RR 3.57 [0.07, 182.64] | 1 study · 40 participants | Very low |
Placebo | no estimate extracted | NR | No studies |